BOSTON & PERTH, Australia--(BUSINESS WIRE)--Global bio-nanotech company pSivida Limited (NASDAQ:PSDV)(ASX:PSD)(Xetra:PSI) today announced the placement of 14,230,768 million fully paid ordinary shares to Australian and European investors issued at AU$0.26 (US$2.00 ADR equivalent) each to raise US$2.9m before costs.
